Novo Nordisk | NVO - Net Income


Novo Nordisk reported DKK4.03B in Net Income for its fiscal quarter ending in June of 2025.





Net Income Change Date
ANI Pharmaceuticals USD 26.27M 18.13M Sep/2025
Aurora Cannabis CAD -51.47M 36.26M Sep/2025
Bausch Health Companies USD -112M 291M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Canopy Growth CAD -1.64M 39.89M Sep/2025
Corcept Therapeutics USD 24.29M 4.62M Dec/2025
Drreddys Laboratories INR 12.1B 2.08B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Novartis USD 3.93B 96M Sep/2025
Novo Nordisk DKK 26.89B 388M Dec/2025
Novo Nordisk DKK 4.03B 25.01B Jun/2025
Pacira USD 5.43M 10.28M Sep/2025
Perrigo USD 7.5M 15.9M Sep/2025
Phibro Animal Health USD 3.18M 3.79M Dec/2024
Prestige Brands USD 46.7M 22.44M Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
Zoetis USD 603M 118M Dec/2025